Researchers in Chicago have developed a method by which to deliver a breast cancer-preventing drug through the skin to avoid some of the nasty side effects associated with oral ingestion of the drug.
Just a year after J&J swooped in to buy up Aragon's game-changing work on prostate cancer in a billion-dollar deal, Roche's Genentech has followed up to buy what remained: a closely-related breast cancer program that promises to change the way that disease is treated.
In a preclinical study, San Francisco-based Nektar Therapeutics found that its investigational cancer drug, NKTR-214, inhibited growth in highly aggressive tumors, showing potential to treat a variety of cancers.
New York's Provista Diagnostics expanded a licensing deal for biomarker and autoantibody technology developed at Arizona State University--concepts first spotted at Harvard Medical School and the Dana-Farber Cancer Institute.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.
Evidence is mounting that circulating tumor cells in the bloodstream, also known as CTCs, are a viable cancer biomarker tool. A team in Germany produced new evidence that their presence, or absence, may be an effective way to measure the survival chance of patients with early breast cancer.
Dartmouth researcher Jack Hoopes has demonstrated that magnetic nanoparticle hyperthermia could be a possible treatment for breast cancer, as he presented in a new preclinical study at the American Association for Cancer Research annual meeting in San Diego.
A harmful gene mutation that increases a woman's risk of developing breast and ovarian cancer may also play a role in brain development, according to new findings by scientists at the Salk Institute for Biological Studies.
In the first detailed glimpse of palbociclib's impact on overall survival--a key feature to the future prospects of this flagship program--the therapy has failed to demonstrate a statistically significant improvement in extending patients' lives after an initial assessment.
Oncology biotech Tesaro will use a cancer test developed by Myriad Genetics to look for tumor types that may respond to PARP inhibitors like niraparib, a Phase III candidate in ovarian cancer and breast cancer, in-licensed from Merck in 2012.